Trial intelligence / Profile preview

Metvix PDT vs Placebo in Primary Nodular Basal Cell Carcinoma

NCT00472108Phase 3Completed

Sponsor
Galderma
Start
Dec 2000
Primary completion
Apr 2002
Modality
Light/Condition-Responsive Prodrugs
Countries
1
01

Overview

A Phase 3 trial of methyl aminolevulinate in basal cell carcinoma (BCC), sponsored by Galderma. Started Dec 2000; status: completed.

02

Drugs

methyl aminolevulinate
03

Conditions

basal cell carcinoma (BCC)

Beyond the preview

Go deeper on NCT00472108.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00472108.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call